Document
type: Class

53011917
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

Academic Article
type: Class

Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
type: Document
type: Entity
language: English
type: Article
type: Thing
type: Generically Dependent Continuant
type: Information Content Entity
type: Continuant
related by: 53011884
type: Academic Article
most specific type: Academic Article
related by: 53011917
related by: 53011901
related by: 53011902

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

Article
type: Class

English
type: Language

53011884
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

Information Content Entity
type: Class

53011902
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

53011901
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

individual
rights: termsOfUse
date: 2026-08-03T17:38:11
publisher: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
type: Document
label: RDF description of Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) - http://irises.unimi.it/resource/item/612969